Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease
Abstract Peptide therapeutics are increasingly used in the treatment of disease, but their administration by injection reduces patient compliance and convenience, especially for chronic diseases. Thus, oral administration of a peptide therapeutic represents a significant advance in medicine, but is...
Enregistré dans:
Auteurs principaux: | Sergei Pechenov, Jefferson Revell, Sarah Will, Jacqueline Naylor, Puneet Tyagi, Chandresh Patel, Lihuan Liang, Leo Tseng, Yue Huang, Anton I. Rosenbaum, Kemal Balic, Anish Konkar, Joseph Grimsby, J. Anand Subramony |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/3ba0d823dad649b18d617f5537b9b8f7 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Targeting GLP-1 receptor trafficking to improve agonist efficacy
par: Ben Jones, et autres
Publié: (2018) -
Role and development of GLP-1 receptor agonists in the management of diabetes
par: Chee W Chia, et autres
Publié: (2009) -
Emerging role of GLP-1 receptor agonists in the treatment of obesity
par: Neff LM
Publié: (2010) -
Emerging role of GLP-1 receptor agonists in the treatment of obesity
par: Lisa M Neff, et autres
Publié: (2010) -
Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
par: Mette Simone Aae Madsen, et autres
Publié: (2019)